Björn Dahlöf Selected Research

Hypertension (High Blood Pressure)

06/2008	Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
04/2008	Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
11/2007	In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
09/2007	Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
04/2007	Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
04/2007	Effect of spironolactone on blood pressure in subjects with resistant hypertension.
02/2007	Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
02/2007	Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
02/2007	Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
01/2007	Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
08/2006	N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
05/2006	Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
03/2006	Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
03/2006	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.
01/2006	Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
11/2005	Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
11/2005	Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
09/2005	The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
07/2005	Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial.
04/2005	Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005	Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
03/2005	The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
03/2005	Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005	Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
02/2005	Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005	Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
09/2004	Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
09/2004	Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
09/2004	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
05/2004	QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
12/2003	Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
01/2003	[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]
12/2002	Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
09/2002	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
09/2002	Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
07/2002	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
03/2002	Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002	Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002	Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
03/2002	Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.

Articles by Research Topic

Disease

40	Hypertension (High Blood Pressure) 06/2008 - 03/2002
20	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 06/2008 - 02/2002
10	Stroke (Strokes) 09/2008 - 04/2003
4	Albuminuria 03/2006 - 09/2004
3	Diabetes Mellitus 11/2007 - 01/2003
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2007 - 06/2004
2	Sclerosis 11/2005 - 10/2004
2	Atrial Fibrillation 03/2005 - 03/2005
1	Bundle-Branch Block (Fascicular Block) 06/2008
1	Heart Failure 01/2006
1	Cardiomegaly (Heart Hypertrophy) 01/2005
1	Fibrosis (Cirrhosis) 08/2004
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 08/2003
1	Vascular Diseases (Vascular Disease) 08/2003
1	Hypertrophy 07/2002

Drug/Important Bio-Agent (IBA)

41	Losartan (Cozaar)FDA Link 06/2008 - 02/2002
18	Atenolol (Tenormin)FDA LinkGeneric 01/2007 - 02/2002
4	atorvastatin (Lipitor)FDA Link 09/2005 - 04/2003
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 09/2008 - 09/2005
2	telmisartan (Micardis)FDA Link 09/2008 - 12/2003
2	Hemoglobins (Hemoglobin)IBA 09/2007 - 05/2006
2	Biological Markers (Surrogate Marker)IBA 08/2004 - 06/2004
2	CholesterolIBA 01/2004 - 04/2003
1	clopidogrel (Plavix)FDA LinkGeneric 09/2008
1	Dipyridamole (Persantine)FDA LinkGeneric 09/2008
1	valsartan (Vals)FDA Link 04/2007
1	Spironolactone (Aldactone)FDA LinkGeneric 04/2007
1	Brain Natriuretic Peptide (Natrecor)FDA Link 08/2006
1	C-Reactive ProteinIBA 08/2006
1	AngiotensinsIBA 11/2005
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2005
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 03/2005
1	Metoprolol (Lopressor)FDA LinkGeneric 12/2003
1	CreatinineIBA 02/2002